Search hospitals > Missouri > Kansas City

Saint Luke's Cancer Institute at Saint Luke's Hospital

Claim this profile
Kansas City, Missouri 64111
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Leukemia
Conducts research for Cancer
Conducts research for Lymphoma
115 reported clinical trials
3 medical researchers
Photo of Saint Luke's Cancer Institute at Saint Luke's Hospital in Kansas CityPhoto of Saint Luke's Cancer Institute at Saint Luke's Hospital in Kansas CityPhoto of Saint Luke's Cancer Institute at Saint Luke's Hospital in Kansas City

Summary

Saint Luke's Cancer Institute at Saint Luke's Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Cancer, Lymphoma and other specialties. Saint Luke's Cancer Institute at Saint Luke's Hospital is involved with conducting 115 clinical trials across 178 conditions. There are 3 research doctors associated with this hospital, such as Timothy Pluard, Janakiraman Subramanian, and Shahzad Raza, MD.

Area of expertise

1Breast Cancer
Global Leader
Saint Luke's Cancer Institute at Saint Luke's Hospital has run 39 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
Stage III
2Lung Cancer
Global Leader
Saint Luke's Cancer Institute at Saint Luke's Hospital has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Saint Luke's Cancer Institute at Saint Luke's Hospital

Breast Cancer
Solid Tumors
Glioblastoma
Gynecologic Cancers
Head and Neck Squamous Cell Carcinoma
Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Samuraciclib + Fulvestrant

for Breast Cancer

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Recruiting1 award Phase 28 criteria
Image of trial facility.

PF-07220060 + PF-07104091

for Breast Cancer

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: Have been diagnosed with Breast Cancer (BC) of either types: Have HR+, HER2- BC Refractory HR-positive/HER2-positive BC Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.
Recruiting1 award Phase 1 & 215 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Luke's Cancer Institute at Saint Luke's Hospital?
Saint Luke's Cancer Institute at Saint Luke's Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Leukemia, Cancer, Lymphoma and other specialties. Saint Luke's Cancer Institute at Saint Luke's Hospital is involved with conducting 115 clinical trials across 178 conditions. There are 3 research doctors associated with this hospital, such as Timothy Pluard, Janakiraman Subramanian, and Shahzad Raza, MD.